Harnessing RNAi-based nanomedicines for therapeutic gene silencing in B-cell malignancies
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Significance: RNA interference (RNAi) holds great promise as a novel therapeutic approach. Small interfering RNAs (siRNAs) that manipulate gene expression in leukocytes could be used to treat blood cancers. However, the lack of strategies for delivering siRNAs to leukocytes systemically has hampered the development of RNAi-based therapeutics. Here, we show that lipid-based nanoparticles coated with anti-CD38 monoclonal antibodies specifically target mantle cell lymphoma (MCL) cells and induce cell-specific therapeutic gene silencing in vivo. CD38-targeted nanoparticles that contain cyclin D1 siRNAs prolong survival of mice bearing MCL lymphomas in the bone marrow. This strategy opens a new avenue for treating MCL that might be applied to other hematological malignancies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Non-viral vectors for gene-based therapy
Yin, H., Kanasty, R. L., Eltoukhy, A. A., Vegas, A. J., Dorkin, J. R., & Anderson, D. G. (2014) · Nature Reviews Genetics · doi:10.1038/nrg3763 · Cited by 3,123 · cited 1×
“The methods that work in vitro (such as electroporation) are not suitable for systemic in vivo application, whereas others (such as viral vectors) raise safety issues (22, 23).”
MethodTargeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma
Wang, M. L., Rule, S., Martin, P., Goy, A., Auer, R., Kahl, B. S., Jurczak, W., Advani, R. H., Romaguera, J. E., Williams, M. E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1306220 · Cited by 1,685
Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo
Jayaraman, M., Ansell, S. M., Mui, B. L., Tam, Y. K., Chen, J., Du, X., Butler, D., Eltepu, L., Matsuda, S., Narayanannair, J. K., et al. (2012) · Angewandte Chemie International Edition · doi:10.1002/anie.201203263 · Cited by 1,267 · cited 6×
“All lipids used for LNP production were purchased from Avanti Polar lipids except for Dlin-MC3-DMA, which was synthesized in our laboratory according to a reported method (14). siRNA molecules were designed and screened by Alnylam Pharmaceuticals.”
BackgroundInfluentialLiving with or without cyclins and cyclin-dependent kinases
Sherr, C. J., & Roberts, J. M. (2004) · Genes & Development · doi:10.1101/gad.1256504 · Cited by 1,089 · cited 1×
“Still, previous studies have shown that the compensatory activity of other D cyclins allows cycD1 knockout mice to be viable and to show only limited developmental defects (37).”
BackgroundMicrofluidic Synthesis of Highly Potent Limit-size Lipid Nanoparticles for In Vivo Delivery of siRNA
Belliveau, N. M., Huft, J., Lin, P. J., Chen, S., Leung, A. K., Leaver, T. J., Wild, A. W., Lee, J. B., Taylor, R. J., Tam, Y. K., et al. (2012) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2012.28 · Cited by 685 · cited 1×
“We next constructed LNPs encapsulating siRNAs using a microfluidic mixing system as previously described (17, 18, 20) (Fig.”
MethodProgress towards in Vivo Use of siRNAs
Behlke, M. A. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.01.001 · Cited by 677 · cited 1×
“RNAi holds great promise as a powerful tool for evaluating the role of specific genes in cellular and disease processes and for therapeutic applications (1, 2).”
BackgroundDeckert, J., Wetzel, M.-C., Bartle, L. M., Skaletskaya, A., Goldmacher, V. S., Vallée, F., Zhou-Liu, Q., Ferrari, P., Pouzieux, S., Lahoute, C., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0695 · Cited by 333
Advances in lipid nanoparticles for siRNA delivery
Tam, Y., Chen, S., & Cullis, P. (2013) · Pharmaceutics · doi:10.3390/pharmaceutics5030498 · Cited by 229
Cohen, Z. R., Ramishetti, S., Peshes-Yaloz, N., Goldsmith, M., Wohl, A., Zibly, Z., & Peer, D. (2015) · ACS Nano · doi:10.1021/nn506248s · Cited by 182
Self-citationLipid nanoparticles for short interfering RNA delivery
Leung, A. K. K., Tam, Y. Y. C., & Cullis, P. R. (2014) · Advances in genetics · doi:10.1016/b978-0-12-800148-6.00004-3 · Cited by 158
Cited by
Targeted drug delivery strategies for precision medicines
Manzari, M. T., Shamay, Y., Kiguchi, H., Rosen, N., Scaltriti, M., & Heller, D. A. (2021) · Nature Reviews Materials · doi:10.1038/s41578-020-00269-6 · Cited by 1,183
Urbanski, L. M., Leclair, N., & Anczuków, O. (2018) · WIREs RNA · doi:10.1002/wrna.1476 · Cited by 389
Lipid nanoparticle technology for therapeutic gene regulation in the liver
Witzigmann, D., Kulkarni, J. A., Leung, J., Chen, S., Cullis, P. R., & van der Meel, R. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.06.026 · Cited by 376
Targeting cancer with mRNA–lipid nanoparticles: key considerations and future prospects
Kon, E., Ad-El, N., Hazan-Halevy, I., Stotsky-Oterin, L., & Peer, D. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00811-9 · Cited by 371
Self-citationLoh, C.-Y., Arya, A., Naema, A. F., Wong, W. F., Sethi, G., & Looi, C. Y. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00048 · Cited by 348
Metadata
- Authors
- Weinstein, S., Toker, I. A., Emmanuel, R., Ramishetti, S., Hazan-Halevy, I., Rosenblum, D., Goldsmith, M., Abraham, A., Benjamini, O., Bairey, O., Raanani, P., Nagler, A., Lieberman, J., & Peer, D.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2015-12-23
- Volume
- 113
- Issue
- 1
- Pages
- E16-22
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2205359822
- Cited by
- 95
- References
- 10
- FWCI
- 3.35
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Harnessing RNAi-based nanomedicines for therapeutic gene silencing in B-cell malignancies. https://app.cochat.ai/papers/10.1073/pnas.1519273113
- The paper
- Weinstein, S., Toker, I. A., Emmanuel, R., Ramishetti, S., Hazan-Halevy, I., Rosenblum, D., Goldsmith, M., Abraham, A., Benjamini, O., Bairey, O., Raanani, P., Nagler, A., Lieberman, J., & Peer, D. (2016). Harnessing RNAi-based nanomedicines for therapeutic gene silencing in B-cell malignancies. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.1519273113
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.